| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC3228 |
| Trial ID | NCT05609045 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | RH109 |
| Phase | Phase1 |
| Recruitment status | Withdrawn |
| Title | A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster for Healthy Adults Who Have Received Homologous or Heterologous Vaccination With 3 Doses of COVID-19 Inactivated and/or mRNA Vaccine(s) |
| Year | 2023 |
| Country | China |
| Company sponsor | Wuhan Rhegen Biotechnology Co., Ltd. |
| Other ID(s) | RH109 CT HK01 |
| Vector information | |||
|
|||
| Cohort1: RH109 | |||||||
|
|||||||
| Cohort2: Placebo | |||||||
|
|||||||